Madrigal Pharmaceuticals (MDGL) vs Summit Therapeutics (SMMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Madrigal Pharmaceuticals (MDGL) has outperformed Summit Therapeutics (SMMT) over the past year, gaining 10.1% versus a loss of 22.3%. Over five years, MDGL leads with a +447.5% price change compared with +241.6% for SMMT. Summit Therapeutics is the larger company by market cap ($14.03 billion vs $10.90 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDGL | SMMT |
|---|---|---|
| Share price | $471.75 | $17.59 |
| Market cap | $10.90B | $14.03B |
| 1-day change | -1.08% | +2.45% |
| YTD return | -18.99% | +0.57% |
| 1-year return | +10.14% | -22.34% |
| 5-year return | +447.46% | +241.55% |
| Forward P/E | 49.01 | — |
| EPS (TTM) | $-12.85 | $-1.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $958.40M | — |
| Revenue growth (YoY) | +432.05% | — |
| Net income (latest FY) | $-288.28M | $-1.08B |
| Operating margin | -31.31% | — |
| Net margin | -30.08% | — |
| 52-week high | $615.00 | $29.23 |
| 52-week low | $393.61 | $12.07 |
| Distance from 52-week high | -23.29% | -39.82% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +44.59% | +69.30% |
| Average volume | 289.24K | 5.87M |
| Shares outstanding | 23.10M | 797.75M |
| Employees | 915 | 265 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MDGL has outperformed SMMT by 32.5 percentage points over the past year.
About Madrigal Pharmaceuticals
MDGL stock →Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.
Healthcare · Biotechnology · 915 employees
About Summit Therapeutics
SMMT stock →Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).
Healthcare · Biotechnology · 265 employees
MDGL vs SMMT FAQ
Which is bigger, Madrigal Pharmaceuticals or Summit Therapeutics?
Summit Therapeutics (SMMT) is larger, with a market capitalization of $14.03B compared with $10.90B for Madrigal Pharmaceuticals (MDGL).
Which stock has performed better over the past year, MDGL or SMMT?
MDGL returned +10.14% over the past 12 months, compared with -22.34% for SMMT (price return, excluding dividends). Past performance does not predict future results.
Are Madrigal Pharmaceuticals and Summit Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.